Top

Published in:

Open Access 01-01-2020 | Dapagliflozin | Review

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes

Authors: Marc Evans, Debbie Hicks, Dipesh Patel, Vinod Patel, Phil McEwan, Umesh Dashora

Published in: Diabetes Therapy | Issue 1/2020

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitor clinical studies in type 1 diabetes mellitus (T1DM) have demonstrated reduced HbA1c and lower glucose variability with increased time in optimal glucose range as well as additional benefits of reductions in weight and insulin dose without increasing the incidence of hypoglycaemia. However, the appropriate use of SGLT2 inhibitor therapies within clinical practise to treat people with T1DM remains unclear. In this article we have used consensus expert opinion alongside the available evidence, product indication and most recent clinical guidance to provide support for the diabetes healthcare community regarding the appropriate use of SGLT2 inhibitors, focussing on specific considerations for appropriate prescribing of dapagliflozin within the T1DM management pathway. Its purpose is to provide awareness of the issues surrounding treatment with dapagliflozin in T1DM as well as offer practical guidance that also includes a checklist tool for appropriate dapagliflozin prescribing. The checklist aims to support clinicians in identifying those people with T1DM most likely to benefit from dapagliflozin treatment as well as situations where caution may be required.

Funding: AstraZeneca UK Ltd.

Available only for authorised users

Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39(3):481–97. https://doi.org/10.1016/j.ecl.2010.05.011.CrossRefPubMedPubMedCentral

Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. N Engl J Med. 2017;376(15):1419–29. https://doi.org/10.1056/NEJMoa1610187.CrossRefPubMedPubMedCentral

Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med. 1994;331(21):1428–36. https://doi.org/10.1056/nejm199411243312107.CrossRefPubMed

Katsarou A, Gudbjornsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3:17016. https://doi.org/10.1038/nrdp.2017.16.CrossRefPubMed

DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet (London, England). 2018;391(10138):2449–62. https://doi.org/10.1016/s0140-6736(18)31320-5.CrossRef

Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86. https://doi.org/10.1056/nejm199309303291401.CrossRefPubMed

Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381–9. https://doi.org/10.1056/nejm200002103420603.CrossRefPubMed

Nathan DM, McGee P, Steffes MW, Lachin JM. Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes. 2014;63(1):282–90. https://doi.org/10.2337/db13-0782.CrossRefPubMed

American Diabetes Association. (7) Approaches to glycemic treatment. Diabetes Care. 2015;38(Suppl):S41–8. https://doi.org/10.2337/dc15-S010.CrossRef

10.

Peters AL, Ahmann AJ, Battelino T, Evert A, Hirsch IB, Murad MH, et al. Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3922–37. https://doi.org/10.1210/jc.2016-2534.CrossRefPubMed

11.

Diabetes Control and Complications Trial Research Group. Hypoglycemia in the diabetes control and complications trial. The diabetes control and complications trial research group. Diabetes. 1997;46(2):271–86.CrossRef

12.

The DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care. 1988;11(7):567–73. https://doi.org/10.2337/diacare.11.7.567.CrossRef

13.

Gubitosi-Klug RA, Braffett BH, White NH, Sherwin RS, Service FJ, Lachin JM. Risk of severe hypoglycemia in type 1 diabetes over 30 years of follow-up in the DCCT/EDIC Study. Diabetes Care. 2017;40(8):1010–6.CrossRefPubMedPubMedCentral

14.

Tamborlane WV. Severe hypoglycemia in youth with T1DM: going, going … but not yet gone. Pediatr Diabetes. 2011;12(1):1–3. https://doi.org/10.1111/j.1399-5448.2010.00754.x.CrossRefPubMed

15.

Beall C, Ashford ML, McCrimmon RJ. The physiology and pathophysiology of the neural control of the counterregulatory response. Am J Phys Regul Integr Comp Phys. 2012;302(2):R215–23. https://doi.org/10.1152/ajpregu.00531.2011.CrossRef

16.

NHS Digital. National Diabetes Audit 2017-18. Report 1: Care Processes and Treatment Targets. 2019. https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/report-1-care-processes-and-treatment-targets-2017-18-full-report. Accessed 24 July 2019.

17.

Petrie JR, Chaturvedi N, Ford I, Brouwers M, Greenlaw N, Tillin T, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):597–609. https://doi.org/10.1016/s2213-8587(17)30194-8.CrossRefPubMedPubMedCentral

18.

Meng H, Zhang A, Liang Y, Hao J, Zhang X, Lu J. Effect of metformin on glycaemic control in patients with type 1 diabetes: a meta-analysis of randomized controlled trials. Diabetes/Metab Res Rev. 2018;34(4):e2983. https://doi.org/10.1002/dmrr.2983.CrossRef

19.

Schopman JE, Hoekstra JB, Frier BM, Ackermans MT, de Sonnaville JJ, Stades AM, et al. Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study. Diabetes Obes Metab. 2015;17(6):546–53. https://doi.org/10.1111/dom.12453.CrossRefPubMed

20.

Farngren J, Persson M, Schweizer A, Foley JE, Ahren B. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab. 2012;97(10):3799–806. https://doi.org/10.1210/jc.2012-2332.CrossRefPubMed

21.

Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2013;19(1):19–28. https://doi.org/10.4158/ep12100.Or.CrossRefPubMed

22.

Guo H, Fang C, Huang Y, Pei Y, Chen L, Hu J. The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2016;121:184–91. https://doi.org/10.1016/j.diabres.2016.08.022.CrossRefPubMed

23.

Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care. 2016;39(10):1702–10. https://doi.org/10.2337/dc16-0691.CrossRefPubMed

24.

Ahren B, Hirsch IB, Pieber TR, Mathieu C, Gomez-Peralta F, Hansen TK, et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care. 2016;39(10):1693–701. https://doi.org/10.2337/dc16-0690.CrossRefPubMed

25.

Liu L, Shao Z, Xia Y, Qin J, Xiao Y, Zhou Z, et al. Incretin-based therapies for patients with type 1 diabetes: a meta-analysis. Endocr Connect. 2019. https://doi.org/10.1530/ec-18-0546.CrossRefPubMedPubMedCentral

26.

DeGeeter M, Williamson B. Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors. J Pharm Pract. 2016;29(2):144–59. https://doi.org/10.1177/0897190014549837.CrossRefPubMed

27.

Hari Kumar KV, Shaikh A, Prusty P. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract. 2013;100(2):e55–8. https://doi.org/10.1016/j.diabres.2013.01.020.CrossRefPubMed

28.

Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabetic Med. 2011;28(10):1176–81. https://doi.org/10.1111/j.1464-5491.2011.03331.x.CrossRefPubMed

29.

Griffin KJ, Thompson PA, Gottschalk M, Kyllo JH, Rabinovitch A. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2014;2(9):710–8. https://doi.org/10.1016/s2213-8587(14)70115-9.CrossRefPubMed

30.

Zhao Y, Yang L, Xiang Y, Liu L, Huang G, Long Z, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains beta-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab. 2014;99(5):E876–80. https://doi.org/10.1210/jc.2013-3633.CrossRefPubMed

31.

Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495–502. https://doi.org/10.1038/nrendo.2011.243.CrossRefPubMed

32.

Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Pongratz RL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011;60(3):890–8. https://doi.org/10.2337/db10-1328.CrossRefPubMedPubMedCentral

33.

Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255–70. https://doi.org/10.1146/annurev-med-051013-110046.CrossRefPubMed

34.

Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care. 2018;41(12):2560–9. https://doi.org/10.2337/dc18-1749.CrossRefPubMed

35.

Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study. Diabetes Care. 2018;41(9):1970–80. https://doi.org/10.2337/dc18-0343.CrossRefPubMedPubMedCentral

36.

Danne T, Cariou B, Banks P, Brandle M, Brath H, Franek E, et al. HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study. Diabetes Care. 2018;41(9):1981–90. https://doi.org/10.2337/dc18-0342.CrossRefPubMed

37.

Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377(24):2337–48. https://doi.org/10.1056/NEJMoa1708337.CrossRefPubMed

38.

Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschope D, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):864–76. https://doi.org/10.1016/s2213-8587(17)30308-x.CrossRefPubMed

39.

Dandona P, Mathieu C, Phillip M, Hansen L, Tschope D, Thoren F, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care. 2018;41(12):2552–9. https://doi.org/10.2337/dc18-1087.CrossRefPubMed

40.

Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial. Diabetes Care. 2018;41(9):1938–46. https://doi.org/10.2337/dc18-0623.CrossRefPubMed

41.

Mathieu C, Dandona P, Phillip M, Oron T, Lind M, Hansen L, et al. Glucose variables in type 1 diabetes studies with dapagliflozin: pooled analysis of continuous glucose monitoring data from DEPICT-1 and -2. Diabetes Care. 2019;42(6):1081–7. https://doi.org/10.2337/dc18-1983.CrossRefPubMed

42.

Dashora U, Patel D, Gregory R, Winocour P, Dhatariya K, Nagi D. Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019). Br J Diabetes. 2019;19:66–72.CrossRef

43.

Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019;42(6):1147–54. https://doi.org/10.2337/dc18-2316.CrossRefPubMedPubMedCentral

44.

Aguillón AR, Mascarello A, Segretti ND, de Azevedo HFZ, Guimaraes CRW, Miranda LSM, et al. Synthetic strategies toward SGLT2 inhibitors. Org Process Res Dev. 2018;22:467–88.CrossRef

45.

European Pharmaceutical Review. EMA accepts marketing authorisation variation for Forxiga in adults with type-1 diabetes 2019. https://www.europeanpharmaceuticalreview.com/news/73381/ema-forxiga-type-1-diabetes/. Accessed 24 July 2019.

46.

National Institute for Health and Clinical Excellence. Technology appraisal guidance [TA597]: Dapagliflozin with insulin for treating type 1 diabetes 2019. https://www.nice.org.uk/guidance/TA597. Accessed 1 Sept 2019.

47.

Scottish Medicine Consortium. SMC2185: Dapagliflozin 5mg film coated tablets (Forxiga®) for treating Type 1 diabetes 2019. https://www.scottishmedicines.org.uk/medicines-advice/dapagliflozin-forxiga-full-smc2185/. Accessed 9 Sept 2019.

48.

Danne T, Cariou B, Buse JB, Garg SK, Rosenstock J, Banks P, et al. improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the intandem program. Diabetes Care. 2019;42(5):919–30. https://doi.org/10.2337/dc18-2149.CrossRefPubMedPubMedCentral

49.

European Medicines Agency. Forxiga : EPAR - medicine overview 2019. https://www.ema.europa.eu/en/documents/overview/forxiga-epar-medicine-overview_en.pdf. Accessed 1 Sept 2019.

50.

Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019. https://doi.org/10.2337/dci19-0028.CrossRefPubMedPubMedCentral

51.

Lega IC, Bronskill SE, Campitelli MA, Guan J, Stall NM, Lam K, et al. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes. Diabetes Obes Metab. 2019. https://doi.org/10.1111/dom.13820.CrossRefPubMed

52.

Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019;170(11):764–9. https://doi.org/10.7326/m19-0085.CrossRefPubMed

53.

Patel NS, Van Name MA, Cengiz E, Carria LR, Weinzimer SA, Tamborlane WV, et al. Altered patterns of early metabolic decompensation in type 1 diabetes during treatment with a SGLT2 inhibitor: an insulin pump suspension study. Diabetes Technol Therap. 2017;19(11):618–22. https://doi.org/10.1089/dia.2017.0267.CrossRef

54.

Dhatariya K. Blood ketones: measurement, interpretation, limitations, and utility in the management of diabetic ketoacidosis. Rev Diabet Stud. 2016;13(4):217–25. https://doi.org/10.1900/rds.2016.13.217.CrossRefPubMed

55.

Kamalakannan D, Baskar V, Barton DM, Abdu TA. Diabetic ketoacidosis in pregnancy. Postgrad Med J. 2003;79(934):454–7. https://doi.org/10.1136/pmj.79.934.454.CrossRefPubMedPubMedCentral

56.

Morrison FJR, Movassaghian M, Seely EW, Curran A, Shubina M, Morton-Eggleston E, et al. Fetal outcomes after diabetic ketoacidosis during pregnancy. Diabetes Care. 2017;40(7):e77–9. https://doi.org/10.2337/dc17-0186.CrossRefPubMedPubMedCentral

57.

Wang YK, Li YH, Wu ST, Meng E. Fournier’s gangrene. QJM. 2017;110(10):671–2. https://doi.org/10.1093/qjmed/hcx124.CrossRefPubMed

58.

Yanar H, Taviloglu K, Ertekin C, Guloglu R, Zorba U, Cabioglu N, et al. Fournier’s gangrene: risk factors and strategies for management. World J Surg. 2006;30(9):1750–4. https://doi.org/10.1007/s00268-005-0777-3.CrossRefPubMed

59.

Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638–42. https://doi.org/10.2337/dc15-1380.CrossRefPubMed

60.

Trend UK. Type 1 diabetes: What to do when you are ill 2018. http://trend-uk.org/wp-content/uploads/2018/03/A5_T1Illness_TREND_FINAL.pdf. Accessed 24 July 2019.

61.

Trend UK. For healthcare professionals: Appropriate use of SGLT2 inhibitors in type 2 diabetes: right person, right medication, right time 2018. https://www.mydiabetesmyway.scot.nhs.uk/admin/UploadedFiles/Napp-HCP_SGLT2_TREND_FINAL.pdf. Accessed 24 July 2019.

62.

Goldenberg RM, Gilbert JD, Hramiak IM, Woo VC, Zinman B. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. Diabetes Obes Metab. 2019;21(10):2192–202. https://doi.org/10.1111/dom.13811.CrossRefPubMed

63.

Garg SK, Peters AL, Buse JB, Danne T. Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: A STICH protocol. Diabetes Technol Therap. 2018;20(9):571–5. https://doi.org/10.1089/dia.2018.0246.CrossRef

64.

Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42(3):400–5. https://doi.org/10.2337/dc18-1444.CrossRefPubMed

65.

Ceriello A, Kilpatrick ES. Glycemic variability: both sides of the story. Diabetes Care. 2013;36(Suppl 2):S272–5. https://doi.org/10.2337/dcS13-2030.CrossRefPubMedPubMedCentral

66.

Ayano-Takahara S, Ikeda K, Fujimoto S, Hamasaki A, Harashima S, Toyoda K, et al. Glycemic variability is associated with quality of life and treatment satisfaction in patients with type 1 diabetes. Diabetes Care. 2015;38(1):e1–2. https://doi.org/10.2337/dc14-1801.CrossRefPubMed

67.

Lu J, Ma X, Zhou J, Zhang L, Mo Y, Ying L, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care. 2018;41(11):2370–6. https://doi.org/10.2337/dc18-1131.CrossRefPubMed

68.

Savage MW, Dhatariya KK, Kilvert A, Rayman G, Rees JA, Courtney CH, et al. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet Med. 2011;28(5):508–15. https://doi.org/10.1111/j.1464-5491.2011.03246.x.CrossRefPubMed

Title: Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
Authors: Marc Evans
Debbie Hicks
Dipesh Patel
Vinod Patel
Phil McEwan
Umesh Dashora
Publication date: 01-01-2020
Publisher: Springer Healthcare
Keywords: Dapagliflozin
Insulins
Empagliflozin
Hypoglycemia
Diabetes
Insulins
Type 1 Diabetes
Published in: Diabetes Therapy / Issue 1/2020
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI: https://doi.org/10.1007/s13300-019-00728-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Real-world Effectiveness of Liraglutide vs. Sitagliptin Among Older Patients with Type 2 Diabetes Enrolled in a Medicare Advantage Prescription Drug Plan: A Retrospective Observational Study

INtegration of care for reaching targetS In Diabetic patiEnts: Design of the INSIDE Study

The Association Between Phosphorylated Neurofilament Heavy Chain (pNF-H) and Small Fiber Neuropathy (SFN) in Patients with Impaired Glucose Tolerance

Insulin Resistance in Type 1 Diabetes Mellitus and Its Association with Patient’s Micro- and Macrovascular Complications, Sex Hormones, and Other Clinical Data

Comparative Effects of Three Kinds of Bariatric Surgery: A Randomized Case–Control Study in Obese Patients

Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page